LoginRegister

    Alembic Pharma gets USFDA approval for bladder drug

    Written by Ruby Khatun Khatun   |  
    Alembic Pharma gets USFDA approval for bladder drug

    New Delhi: Alembic Pharmaceuticals has received US health regulator's nod for a drug used to treat overactive bladder with symptoms of urinary incontinence, urgency, and frequency.


    "The company has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Darifenacin extended-release tablets, 7.5mg and 15mg," Alembic Pharmaceuticals said in a BSE filing today.


    The approved product is equivalent to Enablex of Allergan Pharmaceuticals.


    According to IMS December 2016 data, Darifenacin extended-release tablets had an estimated market size of USD 64 million.


    The company now has a total of 70 ANDA approvals from the USFDA.

    Abbreviated New Drug ApplicationAlembic PharmaAlembic PharmaceuticalsAllergan Pharmaceuticalsapprovalbladder drugDarifenacinDarifenacin extended-release tabletsEnablexfrequencyindian pharma newsoveractive bladderoveractive bladder drugpharma newspharma news indiaurgencyurinary incontinenceUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X